z-logo
Premium
Daclatasvir and asunaprevir for genotype 1b chronic hepatitis C patients with chronic kidney disease
Author(s) -
Kondo Chisa,
Atsukawa Masanori,
Tsubota Akihito,
Shimada Noritomo,
Abe Hiroshi,
Asano Toru,
Yoshizawa Kai,
Okubo Tomomi,
Chuganji Yoshimichi,
Aizawa Yoshio,
Iio Etsuko,
Tanaka Yasuhito,
Iwakiri Katsuhiko
Publication year - 2017
Publication title -
hepatology research
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.123
H-Index - 75
eISSN - 1872-034X
pISSN - 1386-6346
DOI - 10.1111/hepr.12879
Subject(s) - daclatasvir , medicine , kidney disease , renal function , dialysis , adverse effect , gastroenterology , hepatitis c virus , immunology , virus , ribavirin
Aim To evaluate the efficacy and safety of daclatasvir and asunaprevir combined therapy in genotype 1b chronic hepatitis C patients with non‐dialysis chronic kidney disease (CKD). Methods In a multicenter collaborative study, 249 patients received 60 mg daclatasvir (NS5A inhibitor) once a day and 100 mg of asunaprevir (NS3/4A protease inhibitor) twice a day for 24 weeks between September 2014 and September 2015 and were subjected to this analysis. Virological response and adverse events in non‐dialysis patients with CKD (stage 3–5, excluding 5D: dialysis), which was defined as estimated glomerular filtration rate <60 mL/min/1.73 m 2 , were compared with those in patients without CKD. Results Overall, the rates of rapid viral response, end‐of‐treatment response, and sustained virological response (SVR) were 76.7%, 91.2%, and 86.3%, respectively. Among 55 patients with CKD, the rapid viral response, end‐of‐treatment response, and SVR rates were 76.4%, 87.3%, and 83.6%, respectively. Among 194 patients without CKD, they were 76.8, 92.3, and 87.1%, respectively. There were no significant differences in the virological response rates between the two groups ( P  = 0.999, 0.282, and 0.509, respectively). The baseline estimated glomerular filtration rate did not affect the achievement of SVR. The incidence of adverse events in patients with and without CKD were 21.8% and 13.9%, respectively (not significant, P  = 0.142). Conclusion The efficacy and safety of daclatasvir and asunaprevir combined therapy in genotype 1b chronic hepatitis C patients with non‐dialysis CKD are not inferior to those in patients without CKD.

This content is not available in your region!

Continue researching here.

Having issues? You can contact us here